Ryves W J, Dimitrijevic S, Gordge P C, Evans F J
School of Pharmacy, University of London, Department of Pharmacognosy, UK.
Carcinogenesis. 1994 Nov;15(11):2501-6. doi: 10.1093/carcin/15.11.2501.
The human promyelocytic leukaemia cell (HL-60) undergoes differentiation into a macrophage-like form when exposed to both tumour promoting- and non-promoting phorbol esters. We have investigated the effect of the two non-promoting phorbol esters, 12-deoxyphorbol-13-O-phenylacetate (Dopp) and 12-deoxyphorbol-13-O-phenylacetate-20-acetate (Doppa) on HL-60 cultures, and compared them with the tumour promoter 12-O-tetradecanoylphorbol-13-acetate (TPA). All phorbol esters tested were found to be able to stop HL-60 proliferation and induce cell adherence and morphological changes characteristic of differentiation. TPA, fully differentiating at 1 nM, was more potent than Dopp and Doppa, which required 100 nM for full differentiation effects within the 4 day study. Doppa initially appeared weaker than Dopp at inhibiting incorporation of thymidine, the earliest effect studied, but we were able to detect rapid C-20 deacylation of Doppa, converting it to Dopp, using an HPLC protocol presented here. A detailed study of this thymidine incorporation inhibition showed that both TPA (10 nM or greater) and Dopp (500 nM or greater) have very similar time courses, with 50% inhibition occurring at approximately 12 h, in contrast to Doppa which had a significantly delayed time course at all doses tested. Exposure tests indicated that Dopp and Doppa could be washed from the cells much more easily than TPA. The data presented here strongly support the notion that the metabolic conversion of Doppa to Dopp by HL-60 cells was necessary to mediate its differentiating effects. Since protein kinase C (PKC)-beta 1, present in HL-60 cells, has been found to be the only PKC isotype activated so far in vitro by Doppa, our results suggest that activation of this isotype is not sufficient to drive HL-60 differentiation in vivo.
人早幼粒细胞白血病细胞(HL-60)在暴露于促肿瘤和非促肿瘤佛波酯时会分化为巨噬细胞样形态。我们研究了两种非促肿瘤佛波酯,12-脱氧佛波醇-13-O-苯乙酸酯(Dopp)和12-脱氧佛波醇-13-O-苯乙酸酯-20-乙酸酯(Doppa)对HL-60培养物的影响,并将它们与肿瘤促进剂12-O-十四酰佛波醇-13-乙酸酯(TPA)进行比较。所有测试的佛波酯都能阻止HL-60增殖,并诱导细胞黏附以及分化特有的形态变化。TPA在1 nM时能完全诱导分化,比Dopp和Doppa更有效,在为期4天的研究中,Dopp和Doppa需要100 nM才能产生完全的分化效果。Doppa在抑制最早研究的效应即胸苷掺入方面最初似乎比Dopp弱,但我们能够使用此处介绍的高效液相色谱法检测到Doppa快速的C-20脱酰基作用,将其转化为Dopp。对这种胸苷掺入抑制的详细研究表明,TPA(10 nM或更高)和Dopp(500 nM或更高)具有非常相似的时间进程,在大约12小时时出现50%的抑制,相比之下,Doppa在所有测试剂量下时间进程都明显延迟。暴露试验表明,Dopp和Doppa比TPA更容易从细胞中洗脱。此处呈现的数据有力地支持了这样一种观点,即HL-60细胞将Doppa代谢转化为Dopp对于介导其分化作用是必要的。由于HL-60细胞中存在的蛋白激酶C(PKC)-β1是迄今为止在体外被Doppa激活的唯一PKC亚型,我们的结果表明该亚型的激活不足以在体内驱动HL-60分化。